Compare AJANTA PHARMA with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA CADILA HEALTHCARE AJANTA PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 24.7 24.9 99.3% View Chart
P/BV x 6.9 4.4 157.2% View Chart
Dividend Yield % 0.5 0.8 64.9%  

Financials

 AJANTA PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
CADILA HEALTHCARE
Mar-20
AJANTA PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,422352 403.6%   
Low Rs898207 434.7%   
Sales per share (Unadj.) Rs233.5139.2 167.7%  
Earnings per share (Unadj.) Rs44.011.8 373.7%  
Cash flow per share (Unadj.) Rs52.218.6 280.9%  
Dividends per share (Unadj.) Rs9.003.50 257.1%  
Dividend yield (eoy) %0.81.3 61.9%  
Book value per share (Unadj.) Rs255.1101.4 251.7%  
Shares outstanding (eoy) m88.021,023.74 8.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.02.0 247.5%   
Avg P/E ratio x26.423.7 111.1%  
P/CF ratio (eoy) x22.215.0 147.8%  
Price / Book Value ratio x4.52.8 164.9%  
Dividend payout %20.529.8 68.8%   
Avg Mkt Cap Rs m102,081286,033 35.7%   
No. of employees `0006.813.4 50.7%   
Total wages/salary Rs m4,30724,145 17.8%   
Avg. sales/employee Rs Th3,022.610,632.7 28.4%   
Avg. wages/employee Rs Th633.41,801.2 35.2%   
Avg. net profit/employee Rs Th569.1898.5 63.3%   
INCOME DATA
Net Sales Rs m20,554142,531 14.4%  
Other income Rs m2111,139 18.5%   
Total revenues Rs m20,765143,670 14.5%   
Gross profit Rs m5,66424,198 23.4%  
Depreciation Rs m7216,965 10.3%   
Interest Rs m123,418 0.3%   
Profit before tax Rs m5,14314,954 34.4%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2733,198 39.8%   
Profit after tax Rs m3,87012,044 32.1%  
Gross profit margin %27.617.0 162.3%  
Effective tax rate %24.821.4 115.7%   
Net profit margin %18.88.5 222.8%  
BALANCE SHEET DATA
Current assets Rs m11,81287,154 13.6%   
Current liabilities Rs m3,77682,694 4.6%   
Net working cap to sales %39.13.1 1,249.5%  
Current ratio x3.11.1 296.8%  
Inventory Days Days7771 108.3%  
Debtors Days Days8294 87.0%  
Net fixed assets Rs m14,398133,236 10.8%   
Share capital Rs m1751,024 17.1%   
"Free" reserves Rs m22,277102,733 21.7%   
Net worth Rs m22,452103,757 21.6%   
Long term debt Rs m732,146 0.0%   
Total assets Rs m26,962236,866 11.4%  
Interest coverage x444.35.4 8,266.6%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.80.6 126.7%   
Return on assets %14.46.5 220.5%  
Return on equity %17.211.6 148.5%  
Return on capital %23.013.7 167.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68252,752 20.2%   
Fx outflow Rs m2,10214,504 14.5%   
Net fx Rs m8,58038,248 22.4%   
CASH FLOW
From Operations Rs m3,74825,054 15.0%  
From Investments Rs m-2,228-10,123 22.0%  
From Financial Activity Rs m-1,475-10,942 13.5%  
Net Cashflow Rs m453,989 1.1%  

Share Holding

Indian Promoters % 73.8 74.8 98.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 8.3 18.7%  
FIIs % 7.6 5.9 128.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 11.0 154.5%  
Shareholders   20,968 44,069 47.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 441 Points Lower; Nifty Settles Below 15,000-Mark(Closing)

Indian share markets witnessed huge selling during closing hours today and ended their day lower.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS